drugset / Trial / NCT05418582

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

NCT05418582

Phase 1 Completed 40 enrolled Dizal Pharmaceuticals
RandomizedSequentialOpen-labelOther

Summary

This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of DZD9008 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of DZD9008 in healthy adult subjects (Part B).

Timeline

Start
2022-01-25
Primary completion
2022-06-01
Completion
2022-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule
Subject Itraconazole Small molecule
Subject Sunvozertinib Small molecule Oral

Indications

No indication recorded.